“ launched a pharmacokinetic (PK) study on its lead drug candidate Escozine®. The study aims to provide the basis for determining the drug’s exposures in the body. This is part of the latest round of information requested by the United States Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on Escozine® as a potential therapeutic for the SARS-CoV-2 (COVID-19) virus.”
News 
Market Data 
Discover 
AI
